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Abstract
Background: Metabolic abnormalities are common in HIV-infected individuals on antiretroviral therapy (ART), but
the biochemical details and underlying mechanisms of these disorders have not been defined.
Methods: Untargeted metabolomic profiling of plasma was performed for 32 HIV patients with low nadir CD4
counts (<300 cells/ul) on protease inhibitor (PI)-based ART and 20 healthy controls using liquid or gas
chromatography and mass spectrometry. Effects of Hepatitis C (HCV) co-infection and relationships between altered
lipid metabolites and markers of inflammation, microbial translocation, and hepatic function were examined.
Unsupervised hierarchical clustering, principal component analysis (PCA), partial least squares discriminant analysis
(PLS-DA), Random forest, pathway mapping, and metabolite set enrichment analysis (MSEA) were performed using
dChip, Metaboanalyst, and MSEA software.
Results: A 35-metabolite signature mapping to lipid, amino acid, and nucleotide metabolism distinguished HIV
patients with advanced disease on PI-based ART from controls regardless of HCV serostatus (p<0.05, false discovery
rate (FDR)<0.1). Many altered lipids, including bile acids, sulfated steroids, polyunsaturated fatty acids, and
eicosanoids, were ligands of nuclear receptors that regulate metabolism and inflammation. Distinct clusters of
altered lipids correlated with markers of inflammation (interferon-α and interleukin-6), microbial translocation
(lipopolysaccharide (LPS) and LPS-binding protein), and hepatic function (bilirubin) (p<0.05). Lipid alterations
showed substantial overlap with those reported in non-alcoholic fatty liver disease (NALFD). Increased bile acids
were associated with noninvasive markers of hepatic fibrosis (FIB-4, APRI, and YKL-40) and correlated with
acylcarnitines, a marker of mitochondrial dysfunction.
Conclusions: Lipid alterations in HIV patients receiving PI-based ART are linked to markers of inflammation,
microbial translocation, and hepatic function, suggesting that therapeutic strategies attenuating dysregulated innate
immune activation and hepatic dysfunction may be beneficial for prevention and treatment of metabolic disorders
in HIV patients.
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Despite the success of combination antiretroviral therapy
(ART) in reducing HIV-associated morbidity and mortal-
ity, long-term ART is frequently associated with metabolic
abnormalities including dyslipidemia, lipodystrophy, and
insulin resistance [1,2]. These metabolic abnormalities in-
crease the risk of cardiovascular, liver, kidney, bone, and
neurological disorders and the incidence of these disor-
ders is rising as HIV-infected populations age [1,3]. Mech-
anisms driving these abnormalities are multifactorial
including effects of ART (e.g., protease inhibitor (PI)-asso-
ciated dyslipidemia and nucleoside reverse transcriptase
inhibitor (NRTI)-associated mitochondrial toxicity [2-4]),
disease related factors (e.g., CD4 T-cell depletion, inflam-
mation, and unsuppressed viremia), and host factors (e.g.
body mass index, comorbidities, and genetic predispos-
ition) [1,2].
The liver plays a central role in regulating lipid, amino
acid, and carbohydrate metabolism, but few studies have
explored relationships between hepatic dysfunction and
metabolic abnormalities in HIV-infected individuals on
ART. Liver disease represents a leading cause of morbid-
ity and mortality in HIV patients on ART, with hepatic
dysfunction affecting 30-40% of patients [5-7]. Ranging
from mild reversible increases in hepatic enzymes to
fibrosis and decompensation, hepatic dysfunction has
been linked to co-infections with hepatitis B and C
(HBV and HCV), ART-induced hepatotoxicity, and high
prevalence of non-alcoholic fatty liver disease (NAFLD),
which affects 20-70% of HIV-infected individuals [5].
Twenty-five to 40% of HIV-infected individuals in the
United States and Europe are co-infected with HCV. In
these populations, HCV co-infection is associated with
increased rates of lipodystrophy [8,9], hepatic steatosis
[10-12], and insulin resistance [9,13,14], but lower total
cholesterol (TC) and low-density lipoprotein cholesterol
(LDL) [15-17], particularly in patients infected with
HCV genotype 3 [11,12,18]. In HCV mono-infected in-
dividuals, altered cholesterol metabolism is associated
with hepatic steatosis, advanced hepatic fibrosis, and
poor responses to interferon-based therapy [19-21].
Further studies are required to better define metabolic
alterations in HIV subjects with and without HCV co-
infection.
Metabolomics is the unbiased identification and quan-
tification of small molecules in biological fluids. In the
context of disease, metabolomics has been used to iden-
tify novel clinical biomarkers and therapeutic targets.
Here, we performed untargeted metabolomic profiling of
plasma from two independent cohorts of HIV-infected
individuals with late stage disease on PI-based ART to
identify a metabolite signature that distinguishes HIV-
infected from healthy control subjects regardless of HCV
serostatus. We also examined relationships between
altered lipid metabolites and markers of inflammation, mi-
crobial translocation, and hepatic dysfunction.
Methods
Study subjects
HIV subjects (n=32) in the two independent cohorts
were from the National NeuroAIDS Tissue Consortium
(NNTC) (Manhattan HIV Brain Bank, National Neuro-
logical AIDS Bank, California NeuroAIDS Tissue Net-
work, Texas NeuroAIDS Research Center) and CNS
HIV Anti-Retroviral Therapy Effects Research (CHAR-
TER) study. Subjects were enrolled with written in-
formed consent and IRB approval at each study site.
Inclusion criteria were advanced disease (nadir CD4<300
cells/ul), HIV plasma viral load <400 copies/ml, and >1
year on PI-based ART (31% receiving lopinavir (LPV)
plus ritonavir (RTV), 22% receiving nelfinavir (NFV),
16% receiving saquinavir (SQV) plus RTV, 10% receiving
atazanavir (ATV) plus RTV, 6% receiving fosamprenavir
(FPV) plus RTV, 6% receiving indinavir (IDV) plus RTV,
6% receiving SQV and NFV plus RTV, and 3% receiving
amprenavir). Exclusion criteria were current use of lipid
lowering medications, current heavy alcohol consump-
tion, severe hepatotoxicity (defined in accordance with
the AIDS Clinical Trials Group criteria as grades 3 or 4
[22]), and moderate to severe renal insufficiency [23]. To
evaluate effects of HCV co-infection (defined by positive
serostatus), the initial cohort included HIV subjects with
and without HCV co-infection (n=17). Results were vali-
dated in a second independent cohort of HIV subjects
co-infected with HCV (n=15; defined by serostatus).
HIV subjects in the initial and validation cohorts were
matched for age, gender, race/ethnicity, and stage of
HIV disease (nadir and current CD4 counts). Results
were also validated in an independent cohort of HIV
subjects on non-nucleoside reverse transcriptase inhibi-
tors (NNRTI)-based ART (88% on efavirenz and 22% on
nevirapine) matched to HIV subjects on PI-based ART
in the initial and validation cohorts by age, gender, HCV
serostatus, and stage of HIV disease (nadir and current
CD4 counts). Healthy control samples were HIV- and
HCV-negative individuals without a diagnosis of dia-
betes or hyperlipidemia obtained from Bioreclamation
(Westbury, New York) and with informed consent
and IRB approval from Dana-Farber Cancer Institute.
Controls were matched by gender and by gender, age,
race/ethnicity, and smoking in the initial and valid-
ation cohorts, respectively.
Quantification of soluble markers
Plasma levels of interferon (IFN)-α, interleukin (IL)-6,
and IL-2 receptor alpha (RA) were measured using a
Luminex multiplex assay (Bio-Plex System, Bio-Rad La-
boratories). Plasma lipopolysaccaride (LPS) was quantified
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Systems), LPS-binding protein (LBP) (Cell Sciences), and
YKL-40 (Quidel Corporation) were quantified by ELISA.
Metabolomic profiling
Metabolomic profiling was performed by Metabolon
(Durham, NC) using ultra high performance liquid chro-
matography and tandem mass spectrometry (UHLC/
MS
2/MS) optimized for the detection of acidic or basic
metabolites, and gas chromatography (GC)/MS. Plasma
samples were extracted using the MicroLab STAR system
as described [25]. The UHLC/MS
2/MS platform was based
on a Waters ACQUITY UHPLC and Thermo-Finnigan
LTQ mass spectrometer, which consisted of an electrospray
ionization source and linear ion-trap mass analyzer.
Derivatized samples for GC/MS were separated on 5%
phenyldimethyl silicone column with helium as the carrier
gas and a temperature ramp from 60° to 340°C over a 16
minute period. Analysis was performed on a Thermo-
Finnigan Trace DSQ fast-scanning single-quadrupole mass
spectrometer using electron impact ionization. Compounds
were identified by automated comparison of chromato-
graphic and mass spectra properties in samples to
metabolomic library entries of purified standards.
Data processing, bioinformatics, and statistical analysis
Metabolite data was normalized by median centering.
Missing values (33% of metabolites had at least one
missing value) were imputed with the lower limit of de-
tection for a given metabolite. Batch normalization was
performed using the median ratio for each metabolite in
duplicate “anchor” samples across runs. Significantly al-
tered metabolites were defined by a fold change (FC)
>1.3, p-value <0.05 and FDR ≤0.1. Principal component
analysis (PCA), partial least squares discriminant ana-
lysis (PLS-DA), and Random Forest were performed in
the Metaboanalyst web portal (www.metaboanalyst.ca).
Hierarchical clustering of signature metabolites altered
in HIV compared to control subjects was performed in
dChip (www.dchip.org). KEGG API was used to inter-
face with the KEGG database. Additional small molecule
pathways were extracted from Small Molecule Pathways
Database (SMPDB). Quantitative enrichment analysis was
performed in Metabolite Set Enrichment Analysis (MSEA)
software (www.metaboanalyst.ca) using the Metabolic
Pathways library from MSEA and metabolite sets from
Lipid Maps (www.lipidmaps.org). Additional statistical
analyses were performed in R on log-transformed data.
Pearson correlations were used to evaluate relationships
between metabolites (p<0.05, FDR≤0.1). Spearman corre-
lations were used to examine relationships between me-
tabolites and markers of inflammation (IFN-α,I L - 6 ,
IL2RA, and sCD14), microbial translocation (LPS and
LBP), and hepatic function (total bilirubin, bilirubin (E,E),
bilirubin (Z,Z), and albumin), and liver enzymes (alanine
transaminase (ALT), aspartate transaminase (AST), and
alkaline phosphatase (ALP))(p<0.05, FDR≤0.1). Multiple
testing corrections were performed by calculating the false
discovery rate (FDR) using fdrtool.
Results
HIV subject cohorts
Clinical characteristics of HIV subjects in the two co-
horts are shown in Table 1. Both cohorts were predom-
inantly male and African American (median age 45),
with similar nadir and current CD4 T cell counts (median
58 vs. 53 (p=0.314) and 267 vs. 212 cells/ul (p=0.472)) and
suppressed plasma viral loads (median 69 vs. 50 copies/
ml) in initial and validation cohorts, respectively. All HIV
subjects were on ART including at least one protease in-
hibitor for a median of 31 months (IQR: 15–50 months);
75% were on RTV-boosted PI and 25% were on unboosted
PI. 97% of HIVsubjects were taking NRTI inhibitors. Only
three HIV subjects had hyperlipidemia (2 with mildly ele-
vated total cholesterol, LDL, and triglycerides, 1 with high
triglycerides and mildly elevated total cholesterol), one
subject had clinical evidence of lipodystrophy, and one
had diabetes. 38% of HIV subjects had mild-to-moderate
elevations in hepatic aminotransferases (ALT range: 62–
113 IU/L and AST range: 38–133 IU/L) and 19% had ele-
vations in total bilirubin (range: 1.3-4.2 mg/dL) and/or
decreased albumin (range: 2–3.3 g/dL). HCV co-infection
was not associated with higher levels of ALT, AST, or total
bilirubin compared to those without HCV co-infection.
31% of HIV subjects reported past alcohol abuse and one
had current alcohol dependence (assessed by Psychiatric
Research Interview for Substance and Mental Disorders
(PRISM)).
Alterations in the plasma metabolome of HIV subjects are
linked to multiple biosynthetic pathways
Untargeted metabolomic profiling of plasma from 2 in-
dependent cohorts of HIV and control subjects detected
a total of 335 and 349 metabolites in the initial and valid-
ation cohorts, respectively (Figure 1A). To reduce noise in
the data analysis, pre-processing was performed to exclude
xenobiotics, carbohydrates, and metabolites >3-fold differ-
ent between the control groups (p<0.01). By this approach,
227 metabolites detected across both cohorts met accept-
ability criteria and were further analyzed using bioinfor-
matic tools (Additional file 1). PCA revealed a clear
separation of HIV and control metabolomes in both co-
horts (Figure 2A). Consistent with these results, Random
Forest analysis classified HIV vs. control subjects with 96%
and 100% predictive accuracy in initial and validation co-
horts, respectively. 35 metabolites distinguished between
HIV subjects and controls across both cohorts (10 up and
26 down) regardless of HCV serostatus based fold change
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analysis of HIV subjects from the initial cohort with and
without HCVco-infection. Moreover, the majority of these
metabolites (23 of 35), including bile acids, steroids, and
long chain fatty acids (LCFA), were altered in an inde-
pendent cohort of HIV subjects on NNRTI-based ART vs.
matched healthy controls (Additional file 2), indicating
that many of these alterations also occur in HIV patients
not on PI-based ART. Unsupervised hierarchical cluster-
ing of this metabolite set classified HIV vs. control subjects
with 100% accuracy in both cohorts (Figure 1B). To iden-
tify and rank signature metabolites explaining most of the
variance between HIV and control metabolomes, we used
PLS-DA to evaluate variable importance in projection
scores (VIP scores) (Figure 1C). Eleven of 15 top-ranked
VIP scores overlapped between cohorts (p<0.05), corre-
sponding to 3 bile acids (glycocholate (GCA), taurocholate
(TCA), and taurodeoxycholate (TDCA)), 3 steroids (dehy-
droepiandrosterone sulfate (DHEA-S), epiandrosterone
sulfate (EpiA-S), and pregnenolone sulfate), eicosa-
pentaenoic acid (EPA), 5-hydroxyeicosatetraenoic acid
(5-HETE), indolepropionate, phenylacetylglutamine, and
histidylphenylalanine. Thus, we identified a 35-metabolite
signature that distinguishes HIV-infected from healthy
control subjects regardless of HCVserostatus.
Substantial overlap between alterations in the plasma
metabolome of HIV subjects with and without HCV
co-infection
Given the high prevalence of HCV co-infection in HIV-
infected populations and the association between HCV
co-infection and increased rates of lipodystrophy, hepatic
steatosis, and insulin resistance, we next examined the ef-
fects of HCV co-infection on the HIV plasma meta-
bolome. Within the initial cohort, PCA revealed a clear
separation of the plasma metabolomes from HIV subjects
with and without HCVco-infection (Figure 2A). To exam-
ine the effects of HCV co-infection on the HIV plasma
metabolome, we compared metabolic alterations in sub-
groups consisting of HIV subjects with and without HCV
co-infection (Figure 2B). In addition to the 35-metabolite
signature that distinguished HIV subjects from healthy
controls regardless of HCV serostatus (Figure 1B), 11 add-
itional metabolites (2 up and 9 down) (FC>1.3, p<0.05,
FDR<10%) were altered only in HCV-positive subjects
across both cohorts (Figure 2B). Next, we performed a
sub-analysis of HIV subjects with (n=10) and without
HCV co-infection (n=7) and healthy controls (n=8)
matched for age, gender, and race/ethnicity. The majority
of metabolites altered in HIV subjects with HCV co-
infection were also altered in subjects without HCV in-
cluding sulfated steroids, bile acids, essential fatty acids
(EFA), LCFA, fibrinogen cleavage peptides, and trypto-
phan metabolites (Figure 2C and Additional file 3). Com-
pared to HIV subjects without HCV, HCV co-infection
was associated with lower sulfated steroids, essential fatty
acids (EFA), long chain fatty acids (LCFA), fibrinogen
cleavage peptides, and tryptophan metabolites (i.e. trypto-
phan betaine and indolepropionate) and higher plasma
LPS (Figure 2C). Unexpectedly, bile acid levels were simi-
lar in HIV subjects with and without HCV. These results
suggest there is substantial overlap between metabolite
sets altered in HIV subjects with versus without HCV
co-infection in the study cohort. However, HCV co-
infection appears to potentiate some of these metabolic
abnormalities.
Altered bile acid, acylcarnitine, PUFA,
glycerophospholipid, and steroid metabolism in HIV
subjects on PI-based ART
Given substantial overlap between metabolites altered in
HIV subjects with and without HCV co-infection, we
used a merged dataset of all HIV subjects (n=32) and
healthy controls (n=20) for pathway mapping and correl-
ation analysis. In the merged dataset, 58 metabolites dis-
tinguished between HIV subjects and controls (FC>1.3,
p<0.05, FDR<10%), including the 35 signature metabolites
and 23 additional metabolites that approached significance
in the initial and validation cohorts (0.05<p<0.20). Map-
ping these metabolites with KEGG IDs (n=50) to KEGG
and SMPDB pathways identified alterations in multiple
biosynthetic pathways including glycerophospholipid me-
tabolism (lysophosphocholine (LPC)), steroid metabolism
(pregnenolone sulfate, DHEA-S, EpiA-S, and androsterone
sulfate), bile acid biosynthesis (TCA, taurodeoxycholate
(TCDA), GCA, and glycodeoxycholate (GCDA)), LCFA
Table 1 Clinical and demographic characteristics of HIV
subjects in study cohorts
Characteristic Initial cohort
(n=17)
Validation cohort
(n=15)
Age (years)* 45 (42–50) 45 (43–50)
Gender (male) 12 (60%) 15 (83%)
Race (African American) 15 (75%) 9 (50%)
BMI 23.7 (22.9-24.7) 23.9 (22.7-27.2)
HCV seropositive 7 (41%) 15 (100%)
Time on ART (months)* 30 (13–50) 36 (16–50)
CD4 T-cell count (cells/ul)* 267 (107–399) 213 (126–293)
Nadir CD4 T-cell count (cells/ul)* 58 (18–136) 53 (9–132)
Plasma HIV RNA (copies/ml)* 69 (50–181) 50 (50–88)
Total Bilirubin (mg/dL)* 0.6 (0.4-0.9) 0.6 (0.4-0.9)
ALT (IU/L)* 31 (23–77) 27 (20–38)
AST (IU/L)* 36 (25–59) 33 (24–52)
Alkaline Phosphatase (IU/L)* 96 (81–128) 88 (80–128)
Albumin (g/dL)* 4.0 (3.7-4.5) 4.0 (3.7-4.4)
* Median (IQR).
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DPA
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Initial
Validation
LC-MS (+ESI)
LC-MS (-ESI)
GC-MS (+EI)
335 Metabolites
35 Metabolites
Significant in both Cohorts
(FC>1.3, P<0.05, q<0.1)
Validation Cohort
15 HIV+ Subjects
vs
10 Controls
Data Pre-Processing
Initial Cohort
17 HIV+ Subjects
vs
10 Controls
349 Metabolites
227 Metabolites
A
B
C
VIP Score
5 . 15 . 2 0 . 2 0 . 1
5 . 15 . 2 0 . 2 0 . 1 3.0
Figure 1 (See legend on next page.)
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noic acid (DHA), and docosapentaenoic acid (DPA)), ei-
cosanoid biosynthesis (5-HETE, prostaglandin B2 (PGB2),
prostaglandin E2 (PGE2), and thromboxane B2 (TXB2)),
mitochondrial function (carnitine and butyrylcarnitine),
tryptophan metabolism (tryptophan betaine, kynurenine,
and indoleproprionate), the citric acid cycle (fumarate and
malate), and pyrimidine metabolism (uridine, pseudourid-
ine, and 5-methyluridine) (Figure 3). Because >50% of al-
tered metabolites were lipids, we performed MSEA for
113 lipids from the merged dataset (Additional file 4). 11
metabolite sets were enriched in the HIV plasma lipidome
compared to controls (p<0.05, FDR<5%) including bile
acid biosynthesis, steroidogenesis and sulfation, LPC and
acylcarnitine biosynthesis, and pathways involved in fatty
acid biosynthesis, elongation, oxidation, and metabolism
(Figure 4A). Consistent with these results, Welch’s t-tests
identified alterations in several lipid classes including bile
acids, acylcarnitines, PUFA, LPC, and sulfated steroids
(FC>1.3, p<0.05, FDR<10%) (Figure 4B). Four bile acids
and two acylcarnitines were increased and omega-3 and
omega-6 PUFA (AA, EPA, DPA, and DHA), LPC ((LPC
(18:0), LPC (18:1), and LPC (20:4)), and sulfated steroids
(DHEA-S, pregnenolone sulfate, androsterone sulfate and
EpiA-S) were decreased in HIV compared to control sub-
jects. Thus, alterations in the HIV plasma metabolome are
indicative of dysregulated of bile acid, acylcarnitine, PUFA,
LPC, and steroid metabolism.
Identification of lipid abnormalities linked to markers of
inflammation, microbial translocation, and hepatic
function
Next, we examined inter-relationships between alter-
ations in the plasma lipidome and markers of inflamma-
tion, microbial translocation, and hepatic function.
Pearson correlation analysis followed by clustering and
visualization of the correlation matrix identified 3 dis-
tinct clusters of co-modulated lipids (p<0.05, FDR<0.1)
(Figure 5, Additional file 5). In cluster 1, steroids and LPC
were positively correlated. In cluster 2, acylcarnitines and
medium chain fatty acids were positively correlated. In
cluster 3, LCFA were positively correlated. Next, we exam-
ined correlations between these lipid subsets and markers
of inflammation (IFN-α,I L - 6 ,I L - 2 R A ,a n ds C D 1 4 ) ,m i -
crobial translocation (LPS, and LBP), hepatic function
(bilirubin and albumin), and liver enzymes (ALT, AST,
and ALP). In cluster 1, sulfated steroids correlated nega-
tively with IFN-α and IL-6 (p<0.05, FDR<10%) (Figure 5).
In cluster 2, acylcarnitines correlated positively with bile
acids (GCA and TCA) and bilirubin (E,E), a geometric iso-
mer of bilirubin identified by metabolomic profiling. In
Cluster 3, LCFA correlated negatively with LPS, LBP, and
bilirubin (Z,Z) and (E,E). LPS and LBP are markers of mi-
crobial translocation from a damaged gut that have been
previously linked to chronic innate immune activation
[24,26] and hepatic dysfunction (9–10) in HIV infection.
These results identify distinct alterations in the HIV
plasma lipidome linked to markers of inflammation, mi-
crobial translocation, and hepatic function.
Overlap between alterations in the HIV plasma lipidome
and changes previously described in NAFLD/Nonalcoholic
Steatohepatitis (NASH)
Given the high prevalence of NAFLD/NASH in HIV pa-
tients on ART [6,7], we compared alterations in the HIV
plasma lipidome to those previously reported in 3 inde-
pendent studies of HIV-negative patients with NAFLD/
NASH [27-29]. Of 113 lipids detected in plasma, 60
were previously studied in subjects with NAFLD/NASH
and 45 were altered in HIV or NAFLD/NASH. 53% (19/
36) of lipids altered in HIV subjects overlapped with
those altered in NAFLD/NASH, including increased bile
acids and acylcarnitines and decreased LPC, PUFA, and
DHEA-S (Figure 6, Additional file 6). However, 47% (17/
36) of altered lipids were unique to HIV subjects, includ-
ing decreased saturated LCFA and eicosanoids. Thus,
the plasma lipidome of HIV patients on suppressive
ART has overlapping, yet distinctive features compared
to those reported in NAFLD/NASH.
Increased plasma bile acids are associated with
noninvasive markers of liver fibrosis (FIB-4, APRI, and
YKL-40)
Recent studies suggest serum bile acids may represent a
noninvasive marker of liver disease in patients with HCV
[30]. To explore relationships between bile acids and non-
invasive markers of liver fibrosis in HIV patients on ART,
we calculated FIB-4 (age [years] × AST [IU/L]/platelet
count [10
9/L] × (ALT
1/2[IU/L])) and AST-Platelets Ratio
Index (APRI) (AST [IU/L]/platelet count [10
9/L]) scores,
(See figure on previous page.)
Figure 1 Metabolomic profiling of plasma from two cohorts identifies metabolites that distinguish HIV subjects from controls. (A)
Schematic of strategy used to identify plasma metabolites altered in initial and validation cohorts. LC, liquid chromatography; GC, gas
chromatography; MS, mass spectrometry; ESI, electrospray ionization; EI, electron ionization. (B) Unsupervised hierarchical clustering of signature
metabolites (n=35) that distinguish HIV vs. control subjects in initial and validation cohorts (left and right heatmaps, respectively) regardless of
HCV serostatus (FC>1.3, p<0.05, FDR <10%). Red and blue indicate increased and decreased levels, respectively. (C) Top VIP scores with expression
heatmap from PLS-DA models. PLS-DA models were constructed with signature metabolites (n=35) from the initial and validation cohorts. Red
and green indicate increased and decreased levels, respectively.
Cassol et al. BMC Infectious Diseases 2013, 13:203 Page 6 of 17
http://www.biomedcentral.com/1471-2334/13/203B
Initial Cohort
HIV+HCV+ 
vs. 
Controls
Initial Cohort
HIV+HCV-
vs. 
Controls
Validation Cohort
HIV+HCV+
vs. 
Controls
35
- ADpSGEGDFXAEGGGVR
- ADSGEGDFXAEGGGVR
- DSGEGDFXAEGGGVR
- XHWESASXXR
- bradykinin
- arachidonate (20:4n6)
- pentadecanoate (15:0)
-G 3 P
-G P C
- heme
- p-cresol sulfate
Initial Validation
Control
HIV+HCV-
HIV+HCV+
Control
HIV+HCV+
PC1 (30%) PC1 (30.7%)
P
C
1
 
(
1
7
.
7
%
)
P
C
1
 
(
1
2
.
8
%
)
Initial Validation
Control
HIV+HCV-
HIV+HCV+
HIV+HCV-
HIV+HCV+
Control
HIV+HCV+
Control
HIV+HCV+
PC1 (30%) PC1 (30.7%)
P
C
1
 
(
1
7
.
7
%
)
P
C
1
 
(
1
2
.
8
%
)
A
11
C
Figure 2 (See legend on next page.)
Cassol et al. BMC Infectious Diseases 2013, 13:203 Page 7 of 17
http://www.biomedcentral.com/1471-2334/13/203evaluated YKL-40 levels in plasma, and examined associa-
tions between these markers and alterations in bile acids.
FIB-4, APRI, and YKL-40 are non-invasive markers of
liver fibrosis shown to correlate with the Ishak histology
scoring system [31-37]. Using previously described cut-
offs [31,38], 44 and 47% of HIV subjects had intermediate
to high FIB-4 (>1.45) and APRI (>0.5) scores, respectively.
53% of HIV subjects had high (>155 ng/ml) levels of
plasma YKL-40. HIV subjects with intermediate/high FIB-
4 and APRI scores had higher plasma GCA, GDCA, and
TCA compared to those with low scores and controls
(Figure 7). Consistent with these findings, HIV subjects
with high levels of circulating YKL-40 had higher levels of
plasma GCA and TCA. These results suggest that elevated
plasma bile acids are associated with non-invasive markers
of hepatic fibrosis in HIV patients with advanced disease
on PI-based ART.
Discussion
In this study, we characterized the plasma metabolome
of HIV patients with advanced disease (CD4 nadir <300
cells/ul) on PI-based ART and identified a 35-metabolite
signature mapping to lipid, amino acid, and nucleotide
metabolism that distinguished HIV from control subjects
independent of HCV serostatus. Seventy percent of these
altered metabolites were lipids, including endogenous li-
gands for the nuclear receptors FXR, PXR, CAR, and
PPAR such as bile acids, sulfated steroids, and PUFA.
These receptors play important roles in regulating lipid
metabolism, inflammation, and hepatic function. Lipids
regulate diverse cellular processes including metabolic,
inflammatory, and innate immune responses, and imbal-
ances in lipid signaling pathways contribute to diverse
pathologies including insulin resistance and cardiovascu-
lar disease [39-41]. Untargeted metabolomic profiling
represents a powerful tool for deconvoluting these path-
ways and gaining insights important for developing
therapeutic strategies to reduce metabolic disease and
chronic inflammation in HIV patients on ART.
In treatment-naive HIV patients studied prior to the
introduction of ART, dyslipidemia was frequently detec-
ted, and characterized by hypocholesterolemia with and
without hypertriglyceridemia [42,43]. The severity and
frequency of these abnormalities were associated with
decreasing CD4 counts and advanced disease [43,44]. In
HIV patients on ART, dyslipidemia has been tradition-
ally characterized by increased triglycerides, increased
total and LDL cholesterol, and decreased HDL choles-
terol [45]. However, these lipids represent only a small
subset of those in plasma [46]. By profiling 113 plasma
lipids, we identified alterations in several lipid classes
including bile acids, acylcarnitines, sulfated steroids,
and PUFA. Bile acids were increased in HIV patients on
PI-based ART, consistent with a small previous study
(n=11) [47]. Under physiological conditions, bile acids
play an important role in lipid absorption and homeo-
stasis (reviewed in [48]). At high concentrations, how-
ever, bile acids are proinflammatory and hepatotoxic
[48]. Acylcarnitines were also elevated in HIV subjects.
Increased serum acylcarnitines, a marker of incomplete
fatty acid β-oxidation, have been reported in patients
with diabetes, and metabolic, cardiovascular, and mito-
chondrial diseases [49-51]. In rodent models of obesity
and insulin resistance, increased acylcarnitines have
been linked to mitochondrial overload under conditions
of metabolic stress [52,53]. Another important finding
was reduced plasma sulfated steroids including DHEA-S,
EpiA-S, pregnenolone sulfate, and androsterone sulfate.
Reduced DHEA-S has been implicated in aging, age-
related comorbidities (e.g., atherosclerosis and bone me-
tabolism), and immune dysfunction [54]. Furthermore,
previous studies found associations between low DHEA-S
and progression to AIDS, as well as dyslipidemia in HIV
subjects on ART [55,56]. Bioactive PUFA including AA,
EPA, DPA, and DHA were also decreased in the HIV
plasma metabolome. PUFA depletion has been linked to
hepatic triglyceride accumulation, unfolded protein re-
sponses, and increased susceptibility to endoplasmic
reticulum stress [57-59]. Collectively, these alterations
show substantial overlap with those previously reported
in NAFLD and NASH, (i.e., bile acids, acylcarnitines,
LPC, PUFA, and DHEA-S) [27-29], raising the possibil-
ity that mechanisms underlying development of NAFLD
(i.e., lipid peroxidation and mitochondrial dysfunction)
may also contribute to dyslipidemia in HIV patients on
ART. However, other alterations were unique to HIV
patients, including decreased saturated LCFA and eicos-
a n o i d s .T h u s ,t h ep l a s m al i p i d o m eo fH I Vp a t i e n t so n
PI-based ART has overlapping, yet distinctive features
compared to NAFLD/NASH.
(See figure on previous page.)
Figure 2 Metabolic pathways altered in HIV
+HCV
- and HIV
+HCV
+ subjects on PI-based ART. (A) PCA analysis shows separation of control
(blue), HIV
+HCV
- (green), and HIV
+HCV
+ (red) metabolomes (n=227 metabolites) in initial and validation cohorts. (B) Venn diagram showing the
distribution of metabolites altered in HIV
+HCV
+ subjects in initial and validation cohorts (n=46; FC>1.3, p<0.05, FDR<10%). (C) Box plots of
metabolite classes altered in HIV
+HCV
- (n=7) or HIV
+HCV
+ (n=10) subjects compared to controls (n=8) matched for age, gender, and race/
ethnicity. Medians are represented by horizontal bars, boxes span the interquartile range (IQR) and whiskers extend to extreme data points within
1.5 times IQR. Outliers plotted as open circles lie outside 1.5 times the IQR. Grey, orange, and red box plots represent controls, HIV
+HCV
- and HIV
+HCV
+ subjects, respectively. P-values were calculated using Welch’s t-tests. K:T ratio; kynurenine to tryptophan ratio.
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pathways identified alterations in immunomodulatory
pathways including tryptophan catabolism and eicosa-
noid biosynthesis (Figure 3). Despite long-term ART,
tryptophan betaine and indoleproprionate were de-
creased and kynurenine and K:T ratios (an index of
indolamine 2,3-dioxygenase (IDO) activity and trypto-
phan catabolism) were increased in HIV subjects com-
pared to controls. Tryptophan catabolism is regulated by
the balanced expression of IDO/tryptophanyl-tRNA-
synthetase (TTS) [60,61]. Chronic IDO activation, how-
ever, drives immune dysfunction by suppressing T cell
proliferation, increasing production of toxic metabolites
(kynurenine and quinolinic acid), and altering the Th17/
Treg balance, and has been previously linked to dysfunc-
tional T cell responses in HIV patients [60-62]. Another
important finding was decreased eicosanoids (e.g., 5-
HETE, PGB2, PGE2, and TXB2). Eicosanoids, derived
from PUFA, play an important role in the initiation and
resolution of inflammation (reviewed in [63]). Thus,
Figure 3 Metabolites altered in HIV subjects compared to healthy controls map to multiple biosynthetic pathways. Altered metabolites
with KEGG ID from the merged dataset (n=32 HIV and n=20 control subjects; FC>1.3, p<0.05, FDR<0.1) were mapped to KEGG and SMPDB
reference pathways and interaction networks were generated in Cytoscape. Green and red nodes represent metabolites with increased and
decreased levels, respectively. White nodes represent pathways. Asterisks indicate related metabolites detected in only one cohort.
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may contribute to dysregulated inflammatory responses
in HIV patients on PI-based ART. Correlation analysis
identified negative correlations between sulfated steroids
and markers of innate immune activation (IFN-α and
IL-6). Mounting evidence suggests that innate immune
responses regulate cholesterol/sterol metabolism. Sul-
fated steroids correlated inversely with plasma IFN-α,
consistent with previous studies demonstrating that
type I IFNs downregulate sterol metabolism during
anti-viral responses [64,65]. Sulfated steroids also corre-
lated inversely with IL-6. Dysregulated IL-6 production
plays a role in age-related conditions, such as rheuma-
toid arthritis [66,67], osteoporosis [68], atherosclerosis
[69], and Alzheimer's disease [70,71]. Consistent with
our results, IL-6 has been shown to correlate inversely
with serum DHEA-S in aging populations [72]. In aging
mice, dysregulated IL-6 production can be reversed by
supplementing animals with DHEA-S [73]. Thus, the re-
lationship between IL-6 and sulfated steroids in HIV pa-
tients on PI-based ART merits further study.
The FIB-4 and APRI indices represent inexpensive,
accurate (overall accuracy up to 87% and 72%, respect-
ively), and non-invasive markers of liver fibrosis in HIV-
infected individuals with and without HCV co-infection
[31-33,74]. Similarly, circulating YKL-40 has been shown
to correlate with the severity of fibrosis in chronic HCV
infection and alcoholic liver disease [75,76]. Here, we
found that intermediate/high FIB-4 and APRI scores and
high levels of plasma YKL-40 were associated with in-
creased plasma bile acids in HIV subjects on PI-based
ART. Consistent with these findings, elevated serum bile
acids have been reported in patients with cirrhosis and
chronic HCV infection and were shown to correlate with
the severity of liver fibrosis [30,77]. Bile acid levels (GCA
and TCA) were positively correlated with acylcarnitines, a
marker of incomplete fatty acid β-oxidation and mito-
chondrial dysfunction [52,78]. In rat models, bile acids
have been shown to inhibit mitochondrial respiration in a
dose dependent manner [79-81] and to enhance the per-
meability of mitochondria to protons [82]. Our findings,
together with those of previous studies [77,83], suggest
that plasma bile acids may represent a sensitive non-
invasive marker of liver dysfunction in HIV patients.
Elevated plasma LPS has been reported in alcoholic
liver disease [84], NAFLD [85], and inflammatory bowel
disease [86] and predicts progression to end-stage liver
disease in patients with chronic HCV infection [87].
Consistent with these findings, we found plasma LPS
correlated positively with markers of hepatic function
(bilirubin (E,E) and bilirubin (Z,Z)). The liver plays a key
role in clearing LPS from the circulation, so increased
plasma LPS may reflect decreased hepatic clearance
[85,87,88]. In turn, circulating LPS may promote hepatic
dysfunction by increasing hepatic inflammation and fi-
brosis [87]. Unexpectedly, LPS, LBP, and bilirubin ((E,E)
and (Z,Z)) were negatively correlated with LCFA. LCFA
deficiency has been reported in patients with advanced
cirrhosis and other liver diseases (acute hepatitis, cholesta-
sis) [87,89]. Thus, decreased plasma LCFA may be indica-
tive of hepatic dysfunction in HIV patients. Together,
these findings suggest complex inter-relationships be-
tween hepatic dysfunction, microbial translocation, and
dyslipidemia in HIV patients on PI-based ART.
We acknowledge certain limitations of our study. We
selected HIV subjects with advanced disease at increased
risk for dyslipidemia (PI-based ART) and hepatic dys-
function (HCV). Further studies are required to define
metabolic alterations in cohorts who are treatment-naive,
at earlier stages of disease, on specific treatment regimens,
with acute vs. chronic HCV infection, and with clinical
evidence of metabolic abnormalities such as lipodystrophy
and insulin resistance. Importantly, >60% of signature me-
tabolites altered in HIV subjects on PI-based ART were
also altered in an independent cohort of HIV subjects on
NNRTI-based ART including sulfated steroids, bile acids,
and LCFA (Additional file 2), indicating that many of the
metabolite alterations we detected in HIV subjects on PI-
based ART are not unique to this class of ART drugs. Fu-
ture studies are required to better understand which
metabolic abnormalities are associated with ART versus
HIV infection. Individuals in both cohorts were predom-
inantly African American. African Americans have higher
rates of coronary heart disease and metabolic syndrome
compared to Caucasians [90]. Thus, further studies are
needed to investigate these findings in other races/ethnici-
ties. Finally, our study cohort was relatively small. None-
theless, there was sufficient statistical power to identify
metabolite sets with significant differences between HIV
subjects with advanced disease and healthy controls. Des-
pite these limitations, by applying stringent selection cri-
teria, our study identified significant alterations in several
important lipid classes associated with markers of inflam-
mation and hepatic function in HIV patients on PI-based
ART.
In summary, metabolomic profiling identified alterations
in the plasma lipidome of HIV patients on PI-based ART,
including increased bile acids and acylcarnitines and de-
creased sulfated steroids, PUFA, and LPC. Correlation ana-
lysis identified alterations in distinct lipid classes linked to
markers of inflammation, microbial translocation, and hep-
atic function. Future studies are required to determine if
these correlations reflect direct or indirect interactions and
define the mechanisms underlying these inter-relationships.
Many of the altered lipids represent important ligands of
the nuclear receptor superfamily. Bile acids are endogenous
ligands for FXR, which regulates bile acid biosynthesis and
hepatic fatty acid and triglyceride biosynthesis [91]. In
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http://www.biomedcentral.com/1471-2334/13/203mice, FXR activation protects against ritonavir-induced
dyslipidemia and aortic plaque development, reverses insu-
lin resistance and lipid abnormalities, and protects against
hepatic steatosis [92,93]. Sulfated steroids and bile acids are
ligands for PXR and CAR, which regulate expression of
Phase I and II drug-metabolizing enzymes and transporters
and hepatic lipid metabolism [91]. Omega-3 and omega-6
PUFA modulate transcription via interactions with PPARs,
which increase fatty acid oxidation and suppress lipogen-
esis and control inflammation by transrepression of NF-κB,
NFAT, AP-1, and STATs [39,91]. Clinical trials have only
shown modest effects of PPARα (fibrates) and PPARγ
(See figure on previous page.)
Figure 4 Lipid pathways altered in HIV subjects on PI-based ART. (A) Quantitative Enrichment Analysis (QEA) performed using MSEA. QEA is
based on the globaltest algorithm which uses a generalized linear model to estimate a Q-statistic for each metabolite set. Lipid metabolites
(n=113) from the merged dataset consisting of all HIV subjects (n=32) and controls (n=20) were inputted into MSEA and enrichment was
assessed using the MSEA Metabolic Pathway library (n=88) and custom metabolite sets derived from Lipid Maps (n=5). Pathways were considered
enriched when p<0.05 and FDR<5%. (B) Box plots of major lipid classes altered in HIV subjects (n=32) compared to controls (n=20). Medians are
represented by horizontal bars, boxes span the interquartile range (IQR) and whiskers extend to extreme data points within 1.5 times IQR. Outliers
plotted as open circles lie outside 1.5 times the IQR. Blue and red represent controls and HIV subjects, respectively. P-values were calculated using
Welch’s t-tests.
P<0.05 P<0.05
Figure 5 Correlation matrix reveals relationships between clusters of lipids and markers of inflammation and hepatic function. The
Pearson correlation matrix was constructed in R using the heatmap.2 function. Significant correlations had a −0.35> r >0.35, p<0.05, and
FDR<10% (Additional file 5). Red and blue indicate positive and negative correlations, respectively (see Color Key).
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Figure 6 The HIV plasma lipidome has overlapping yet distinctive features compared to alterations in NAFLD/NASH. Venn diagram
depicting overlap between metabolites altered in the same direction in HIV subjects on PI-based ART and HIV-negative subjects with NAFLD or
NASH (n=45, Additional file 6). NAFLD and NASH data sets were based on 3 published studies [27-29].
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Figure 7 Increased plasma bile acids are associated with intermediate/high FIB-4 and APRI scores and high YKL-40. Bar graphs showing
bile acid levels (scaled intensity) in healthy controls (white), and HIV subjects with low (pink) vs. intermediate/high FIB-4 or APRI scores or high
YKL-40 levels (red). P-values were calculated using Welch’s t-tests.
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ART lipoatrophy [94,95], while other studies suggested
these drugs may be useful in treating ART-associated dia-
betes and NAFLD [96].
Conclusions
By untargeted metabolomic profiling, this study provides
better understanding of metabolic abnormalities in HIV
patients with advanced disease on PI-based ART. Lipid
abnormalities were linked to markers of inflammation,
microbial translocation, and hepatic function, suggesting
that therapeutic strategies attenuating innate immune
activation and hepatic dysfunction may offer new ap-
proaches for prevention and treatment of dyslipidemia
on PI-based regimens. Conversely, reversing lipid abnor-
malities in HIV patients may be beneficial for attenuat-
ing inflammation, immune dysfunction, and hepatic
dysfunction. Plasma bile acids may represent a sensitive
non-invasive marker of liver dysfunction in HIV patients
on ART. Untargeted metabolomic profiling represents a
powerful tool for gaining a systems-level understanding
of metabolic alterations and their relationship to dys-
function involving other organ systems that will be im-
portant for developing therapeutic strategies targeting
metabolic disease and chronic inflammation in HIV pa-
tients on ART.
Additional files
Additional file 1: Alterations in the plasma metabolome of HIV
patients on PI-based ART compared to healthy controls. Shown is
682 the total dataset of 227 metabolites detected in the initial and
validation 683 cohorts following data pre-processing. Significantly altered
metabolites 684 were defined by a fold change (FC) >1.3, p-value <0.05,
and FDR ≤0.1.
Additional file 2: Majority of signature metabolites are altered in
an independent cohort of HIV subjects on NNRTI-based ART. An
independent 674 cohort of HIV subjects on NNRTI-based ART (n=8) was
matched to HIV 675 subjects in initial and validation cohorts by age,
gender, HCV serostatus, 676 and stage of HIV disease (nadir and current
CD4 count). Significantly 677 altered metabolites were defined by a FC
>1.3, p-value ≤0.1 and FDR 678 ≤0.1 compared to healthy controls (n=8)
matched for age, gender, and 679 race/ethnicity.
Additional file 3: Sub-analysis of HIV plasma metabolome
according to HCV serostatus. Analysis was performed on a subset of
HIV subjects with (n=10) and without HCV co-infection (n=7) matched for
age, gender, and race/ethnicity. Shown is the total dataset of 227
metabolites detected in the initial and validation cohorts following data
pre-processing. Significantly altered metabolites were defined by a
FC >1.3, p-value ≤0.1 and FDR ≤0.1 compared to healthy controls (n=8)
matched for age, gender, and race/ethnicity.
Additional file 4: Alterations in the plasma lipidome of all HIV
subjects compared to controls. Shown are 113 lipids detected in the
merged dataset of all HIV subjects on PI-based ART (n=32) compared to
healthy controls (n=20). Significantly altered metabolites were defined by
a FC >1.3, p-value <0.05 and FDR ≤0.1.
Additional file 5: Pearson correlation analysis of lipid metabolites
detected in plasma from HIV patients on PI-based ART. Pearson
correlation analysis was performed in R using cor.test function. FDR were
generated in R using fdrtool. Shown are correlation coefficients (p-values)
(FDR).
Additional file 6: Lipid metabolites detected in plasma from HIV
patients on PI-based ART and HIV-negative individuals with NAFLD/
NASH. NAFLD and NASH datasets were based on results from 3
previously published studies [36-38]. Red metabolites were altered in HIV
patients compared to healthy controls in the present study or were
previously reported to be altered in patients with NAFLD or NASH
compared to healthy controls.
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